Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Merck (MRK) drops as full-year forecast misses consensus
February 2, 2023 6:51 AM EST(Updated - February 2, 2023 1:20 PM EST)
Shares of Merck (NYSE: MRK) tumbled more than 4% Thursday despite the New Jersey-based pharmaceutical giant reporting stronger-than-expected FQ4 results.
Merck reported Q4 EPS of $1.62 on revenue of $13.8 billion, beating the consensus for earnings of $1.53 on revenue of $13.65B. Molnupiravir sales fell 13% year-over-year to $825 million, still much higher than the consensus of $376M. Keytruda sales rose 19% to $5.45B, in line with the analyst... More
Merck (MRK) Tops Q4 EPS by 9c; Guides FY23 EPS Below the Street
February 2, 2023 6:31 AM ESTMerck (NYSE: MRK) reported Q4 EPS of $1.62, $0.09 better than the analyst estimate of $1.53. Revenue for the quarter came in at $13.8 billion versus the consensus estimate of $13.65 billion.
GUIDANCE:
Merck sees FY2023 EPS of $6.80-$6.95, versus the consensus of $7.36. Merck sees... More
